MY ACCOUNT | NEWSLETTER |

Colleen Flesher appointed co-CEO for Movora


Colleen Flesher has been appointed the new co-CEO of veterinary MedTech leader Movora, an operating company of Vimian. Flesher assumed her position Dec. 1 and succeeded Patrick Gendreau and Christopher Sidebotham.

Flesher has more than 20 years of experience in leadership positions in the global MedTech sector. She joined Movora as COO in October 2022 after three years as president and general manager for Lima Corporate, a leading provider of orthopedic implants to human healthcare. 

Prior to that Flesher spent almost 10 years at Johnson & Johnson's MedTech divisions in managerial positions within sales, marketing, product development and innovation.

Fredrik Ullman, chief executive officer of Vimian Group, said that with Flesher onboard, the company is ready to take the next step in our succession plans for Movora. 

“Together with co-chief executive officer Guy Spörri and the rest of the leadership team in Movora, we will continue to deliver on our strategic agenda strengthening and broadening our global position in veterinary MedTech," he said in a news release

About Movora

Movora is a global provider of orthopedic implants sold to veterinarians, veterinary surgeons and universities, focused on enhancing the mobility and quality of life for pets everywhere.

Through its brands, BioMedtrix, Everost, KYON, IMEX Veterinary, Spectrum Instruments and Veterinary Orthopedic Implants, it offers one of the broadest product portfolios within companion animal orthopedics, ranging from fracture plates to complete hip replacement systems. Movora also believes in supporting veterinary professionals throughout their careers and offers one of the most comprehensive calendars of continuing education courses in the industry, teaching DVMs and Veterinary Surgeons new techniques and procedures. Movora is a single resource for industry-leading medical technology to the veterinary space - from classroom to clinic. 

Movora has regional headquarters in Florida, USA; Ontario, Canada; Zurich, Switzerland; and Tokyo, Japan. Learn more by visiting movora.com.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Comparison of two host cell range variants of feline immunodeficiency virus

Like0
Dislike0

Canine babesiosis: a perspective on clinical complications, biomarkers, and treatment

Like0
Dislike0

The use of growth promoters in swine nutrition: Problems and perspectives concerning public health and swine production

Like0
Dislike0

Penn Vet Announces Interim Leadership for the Department of Clinical Sciences and Advanced Medicine, and Ryan Hospital

Like0
Dislike0

Parnell Launches nixiFLOR® - First FDA-Approved Generic Florfenicol + Flunixin Combination for BRD

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top